Waters experienced some sluggishness in the US market in the quarter, and the firm noted that its pharma business, in particular, had seen a shift toward Europe.
The agreement brings together Biognosys' Spectronaut Pulsar DIA software and Waters' SONAR data-independent acquisition mass spectrometry method.
The company posted Q2 revenues of $558.3 million, up from $536.6 million in Q2 2016 and beating the average Wall Street estimate of $553.1 million.
Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.
As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.
The approval covers Waters' Acquity UPLC and Acquity UPLC I-Class systems, as well as its Xevo TQD, Xevo TQ-S micro, and Xevo TQ-S mass spectrometers.
With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio.
Driven by strong demand from the company's pharma customers, it posted sales of $498 million, beating the average Wall Street estimate of $488.6 million.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.